Archives

Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy

`s-Hertogenbosch,
The Netherlands, 21 May 2019. Amphera B.V., an advanced-clinical-stage
biotechnology company developing dendritic cell therapies to treat cancer,
announces that it has recruited the first patients to a phase II study of
MesoPher to treat pancreatic cancer.

REACtiVe
(Rotterdam pancrEAtic cancer Vaccination trial) is an open-label phase II study
in 10 adult patients with surgically resected pancreatic cancer who have
received adjuvant standard of care treatment.

MesoPher, a personalised immuno-oncology cell therapy, is comprised
of autologous dendritic cells loaded with PheraLys, Amphera’s proprietary
allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for
mesothelioma, contains a broad-spectrum of tumour-associated antigens,
many of

Amphera is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer.

As a result of the selection, Amphera will be able to pitch at the Global Entrepreneurship Summit (GES) and will be offered a trip to Silicon Valley by the Ministry of Economic Affairs and Climate Change. The GES will give Amphera the opportunity to learn how to scale up their innovation faster and take the step from startup to scale-up.

The 10 winners of the Academic Startup